This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Tobacco  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Definite Promise, But No Panacea

Robert C. Klesges, PhD; Karen C. Johnson, MD, MPH; Grant Somes, PhD

JAMA. 2006;296:94-95.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In this issue of JAMA, Gonzales and colleagues,¹ Jorenby and colleagues,² and Tonstad and colleagues³ report the results of 3 randomized trials on the efficacy of the nicotinic acetylcholine receptor partial agonist varenicline for achieving smoking cessation. For the clinician and the lay public, the major question from these trials is simply this: How effective and useful is varenicline for smoking cessation?

These 3 trials have several strengths that cogently argue that varenicline is efficacious for smoking cessation. Instead of the traditional 2-group active drug/placebo trial, 2 studies^1-2 included a third group in which varenicline was compared with bupropion, a known efficacious first-line stop smoking agent.⁴ The trial by Jorenby et al² showed significantly better long-term (ie, at 52 weeks) cessation rates with use of varenicline compared with bupropion, and the trial by Gonzales et al¹ showed . . . [Full Text of this Article]

Author Affiliations: Department of Preventive Medicine, University of Tennessee Health Science Center (Drs Klesges, Johnson, and Somes); and Division of Epidemiology and Cancer Control, St Jude Children's Research Hospital (Dr Klesges), Memphis.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial
David Gonzales, Stephen I. Rennard, Mitchell Nides, Cheryl Oncken, Salomon Azoulay, Clare B. Billing, Eric J. Watsky, Jason Gong, Kathryn E. Williams, Karen R. Reeves, and for the Varenicline Phase 3 Study Group
JAMA. 2006;296(1):47-55.
ABSTRACT | FULL TEXT  

Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation: A Randomized Controlled Trial
Douglas E. Jorenby, J. Taylor Hays, Nancy A. Rigotti, Salomon Azoulay, Eric J. Watsky, Kathryn E. Williams, Clare B. Billing, Jason Gong, Karen R. Reeves, and for the Varenicline Phase 3 Study Group
JAMA. 2006;296(1):56-63.
ABSTRACT | FULL TEXT  

Effect of Maintenance Therapy With Varenicline on Smoking Cessation: A Randomized Controlled Trial
Serena Tonstad, Philip Tønnesen, Peter Hajek, Kathryn E. Williams, Clare B. Billing, Karen R. Reeves, and for the Varenicline Phase 3 Study Group
JAMA. 2006;296(1):64-71.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

{blacktriangledown}Varenicline for smoking cessation
DTB 2008;46:33-36.
ABSTRACT | FULL TEXT  

Pharmacologic Therapy: Novel Approaches for Chronic Obstructive Pulmonary Disease
Bailey and Tashkin
Proc Am Thorac Soc 2007;4:543-548.
ABSTRACT | FULL TEXT  

Other articles noted
Evid. Based Med. 2006;11:191-192.
FULL TEXT  

Is a New Smoking-Cessation Drug on the Horizon?
Journal Watch Cardiology 2006;2006:5-5.
FULL TEXT  

New Drug for Smoking Cessation
JWatch General 2006;2006:2-2.
FULL TEXT  

What's new in the other general journals.
Tonks
BMJ 2006;333:141-142.
FULL TEXT